P501 Incidence and therapeutic management/treatment of very early onset inflammatory bowel disease during 2015-2020.

Ninh, G.(1);Wewer, V.(1);Jakobsen, C.(1);

(1)Copenhagen University Hospital- Hvidovre, Department of Pediatrics, Hvidovre, Denmark


To investigate the incidence of very early onset inflammatory bowel disease (VEO-IBD) in a cohort representing two regions in Denmark during the period 2015-2019 and to assess the medical and surgical treatment.


All patients diagnosed with VEO-IBD within The Capital Region and The Zealand Region from January 1, 2015 to July 1, 2020 were included. Demographic and clinical data and medical and surgical treatment were extracted from the files.


Forty patients with VEO-IBD were identified. The incidence rate was 2.0/100,000 (CI 95% 0.8-5.9) during the 2015-2019. Totally 35 patients (87.5%) received immunomodulatory therapy during follow-up. The cumulative risk of receiving immunomodulatory therapy after 1 year, 3 years and 5 years was 58% (95% CI 39-71), 88% (95% CI 70-95) and 91% (95% CI 73-97) respectively. Totally 23 patients (57.5%) received biological therapy. The cumulative risk of receiving biological therapy after 1 year, 3 years and 5 years was 37% (95% CI 19-50), 46% (95% CI 27-60) and 57% (95% CI 36-71) respectively. Six patients (15%) received vedolizumab. Four patients (10%) with VEO-IBD underwent a colectomy during the follow-up period of which two patients received vedolizumab.


The incidence of VEO-IBD was 2.0/100,000. Medical treatment with immunomodulators and biological therapy was used extensively, possibly reducing surgery. However, medical treatment remains a complicated balancing of the effect (anti-inflammatory), side effect (cancer risk) and surgery in VEO-IBD.